高剂量、高频度乌司奴单抗治疗重度化脓性汗腺炎患者。
High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.
机构信息
Department of Dermatology, Duke University School of Medicine, Durham, NC, USA.
Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
出版信息
Br J Dermatol. 2022 Sep;187(3):417-419. doi: 10.1111/bjd.21066. Epub 2022 May 18.
PMID:35192196
Abstract
In this case series, ustekinumab therapy demonstrated efficacy in some patients with severe hidradenitis suppurativa previously treated with adalimumab and/or infliximab. Larger prospective studies are needed to evaluate ustekinumab as a treatment option for recalcitrant hidradenitis suppurativa.
摘要
在本病例系列中，乌司奴单抗治疗在一些先前接受阿达木单抗和/或英夫利昔单抗治疗的重度化脓性汗腺炎患者中显示出疗效。需要更大规模的前瞻性研究来评估乌司奴单抗作为难治性化脓性汗腺炎的治疗选择。
Zotero 插件